Literature DB >> 6756932

Antihypertensive activity of once daily metoprolol alone and with chlorthalidone and comparison with a twice daily regimen.

G Muiesan, E Agabiti-Rosei, A Carotti, L Corea, P Innocenti, C Montervino, R Prezioso, G Romanelli, M Toso, M Motolese.   

Abstract

In a multicentre, double-blind (DB), within-patient study, the antihypertensive effectiveness and tolerability of two oral administration schedules of metoprolol (M) 100 mg b.i.d. versus 200 mg once daily (o.d.), were investigated in 103 outpatients with mild to moderate essential hypertension. The study lasted 14 weeks and was divided into 3 periods: a) a weeks of single-blind (SB) placebo wash-out; b) 4 weeks of SB administration of M 100 mg b.i.d.; at the end of the second week of this period, chlorthalidone (C) 25 mg was added in patients with a recumbent diastolic blood pressure (BP) still greater than 95 mmHg and was continued throughout the following period; and c) DB cross-over administration of M 200 mg/d for 4 weeks on a b.i.d. schedule and 4 weeks on a once daily schedule. In comparison with pretreatment values, heart rate and systolic and diastolic BP were reduced (p less than 0.001) by both M administration schedules; there was no differences between the once and twice daily treatment regimens. During M once daily, betablockade was still maintained over 24 hours or longer, as the heart rate remained significantly lower than the basal value. In 57 patients, C was added at the end of the second week of SB M administration, and a further decrease in BP was observed; again, there was no significant change during once and twice daily M administration. Unwanted effects during M treatment were of minor severity, and the majority occurred when C, too, was added.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6756932     DOI: 10.1007/bf00547555

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Metoprolol or atenolol for mild-to-moderate hypertension.

Authors:  O Lyngstam; L Rydén
Journal:  Lancet       Date:  1979-09-22       Impact factor: 79.321

2.  Antihypertensive activity of alpha-methyldopa on a twice daily regimen in comparison to metoprolol. A multi-centre controlled clinical trial.

Authors:  G Muiesan; E Agabiti-Rosei; C Alicandri; M Motolese
Journal:  Clin Exp Pharmacol Physiol Suppl       Date:  1978

3.  Beta-blockers: once or three times a day?

Authors:  T Reybrouck; A Amery; R Fagard; P Jousten; P Lijnen; E Meulepas
Journal:  Br Med J       Date:  1978-05-27

4.  Influence of once-daily administration of beta-adrenoceptor antagonists on arterial pressure and its variability.

Authors:  R D Watson; T J Stallard; W A Littler
Journal:  Lancet       Date:  1979-06-09       Impact factor: 79.321

5.  Comparison of metoprolol as hydrochlorothiazide and antihypertensive agents.

Authors:  O L Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

6.  The relative activities of atenolol and metoprolol on the cardiovascular system of man [proceedings].

Authors:  J D Harry; J M Cruikshank; J M Young
Journal:  Br J Clin Pharmacol       Date:  1980-03       Impact factor: 4.335

7.  Maximal exercise power after a single dose of metoprolol and of slow-release metoprolol.

Authors:  H Folgering; M van Bussel
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

8.  Seven years on a selective beta-blocker - metoprolol. A long-term study of women with arterial hypertension.

Authors:  C Bengtsson
Journal:  Ann Clin Res       Date:  1981

9.  Once-daily metoprolol in primary hypertension.

Authors:  B E Karlberg; O Nilsson; K Tolagen; E Nitelius; U Waern
Journal:  Clin Pharmacol Ther       Date:  1979-04       Impact factor: 6.875

10.  Duration of action of beta blockers.

Authors:  S R Johansson; M McCall; C Wilhelmsson; J A Vedin
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

View more
  1 in total

1.  Documentation of an instrument for assessment of subjective CNS-related symptoms during cardiovascular pharmacotherapy.

Authors:  C Dahlöf; E Dimenäs; B Olofsson
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.